Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient

This is an open-label study that will be conducted at three sites in China to characterize the PK/PD profile, safety and tolerability of Recombinant Human Serum Albumin/interferon alpha2b Fusion Protein in HBV subjects. Subjects will receive a single dose of Recombinant Human Serum Albumin/interferon alpha2b Fusion Protein or active comparator Pegasys at Day 0. A multipule-dose administration in HBV subjects will last 12 weeks after four weeks washout period.

Inclusion criteria

• HBV patients who have positive HBeAg or HBeAb
• Must be healthy males or females between 18 to 60 years old
• Must have a body mass index (BMI) of 18 to 30 kg/m2
• HBV DNA≥2000 IU/mL
• ALT≥1.3 ULN and ≤10 ULN

Exclusion criteria

• Administrated a nucleoside analogues (acid) or interferons against hepatitis B virus drugs, immunosuppressants, immune regulator before 6 months;Or any other against hepatitis b virus therapy at the same time.
• Participated in other clinical trials within a month.
• Allergic to interferon.
• T-Bil ≥2 ULN. ALB<35g/L. PT≥4s.
• Positive HCV-Ab,HEV-Ab,EBV-Ab,CMV-Ab,TPPA,HIV-Ab.
• Organ transplant patients, except cornea or hair transplantation.
• Other hepatopathy exclude NAFLD .
• Drug addiction or alcohol dependence.
• Malignancy(except cured cervical carcinoma in situ, BCC, squamous cell carcinoma) except liver history.
• Serious retinal disease.
• Active hemorrhagic disease or severe hematopoietic dysfunction or blood coagulation disorder.
• Autoimmune disease.
• Uncontrolled diabetes or thyroid disease or beyond grade 2 blood pressure.
• WBC<3×109/L or ANC<1.5 ×109/L or PLT<90 ×109/L or HGB<ULN.
• HCC or AFP>100ng/mL.
• Chronic kidney disease or sCr>ULN.
• Lactating women or pregnancy.
• Cardiovascular and cerebrovascular events within 6 months.
• Neurological or psychiatric disease or family history.